InVitae Corp (NVTA) Receives Average Recommendation of “Hold” from Analysts

Shares of InVitae Corp (NYSE:NVTA) have been assigned a consensus rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $11.00.

Several brokerages have commented on NVTA. JPMorgan Chase & Co. cut their target price on InVitae from $13.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, February 13th. Benchmark cut their target price on InVitae from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, February 13th. Leerink Swann cut their target price on InVitae from $14.00 to $12.00 and set an “outperform” rating for the company in a research note on Tuesday, November 7th. BidaskClub downgraded InVitae from a “hold” rating to a “sell” rating in a research note on Thursday, November 2nd. Finally, ValuEngine downgraded InVitae from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd.

Large investors have recently added to or reduced their stakes in the business. Lakeview Capital Partners LLC purchased a new stake in shares of InVitae in the 3rd quarter valued at about $117,000. Teacher Retirement System of Texas purchased a new stake in shares of InVitae in the 4th quarter valued at about $116,000. Gabelli Funds LLC purchased a new stake in shares of InVitae in the 3rd quarter valued at about $131,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of InVitae in the 3rd quarter valued at about $133,000. Finally, Granite Springs Asset Management LLC purchased a new stake in shares of InVitae in the 4th quarter valued at about $132,000. 69.71% of the stock is currently owned by hedge funds and other institutional investors.

Shares of InVitae (NVTA) traded up $0.10 during midday trading on Friday, reaching $6.53. The company’s stock had a trading volume of 407,204 shares, compared to its average volume of 1,060,000. InVitae has a fifty-two week low of $5.15 and a fifty-two week high of $11.88. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.33. The company has a market cap of $345.73 and a P/E ratio of -2.47.

InVitae (NYSE:NVTA) last issued its earnings results on Monday, February 12th. The medical research company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.17). InVitae had a negative return on equity of 134.68% and a negative net margin of 180.85%. The company had revenue of $25.40 million during the quarter, compared to the consensus estimate of $24.18 million. During the same quarter in the prior year, the business earned ($0.69) EPS. The firm’s revenue for the quarter was up 175.0% compared to the same quarter last year. equities research analysts predict that InVitae will post -2.28 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “InVitae Corp (NVTA) Receives Average Recommendation of “Hold” from Analysts” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/24/invitae-corp-nvta-receives-average-recommendation-of-hold-from-analysts.html.

About InVitae

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply